0.48
-0.006(-1.23%)
Currency In USD
| Previous Close | 0.49 |
| Open | 0.5 |
| Day High | 0.5 |
| Day Low | 0.47 |
| 52-Week High | 3.65 |
| 52-Week Low | 0.25 |
| Volume | 1.24M |
| Average Volume | 4.06M |
| Market Cap | 14.6M |
| PE | -0.13 |
| EPS | -3.74 |
| Moving Average 50 Days | 0.45 |
| Moving Average 200 Days | 0.77 |
| Change | -0.01 |
If you invested $1000 in Moleculin Biotech, Inc. (MBRX) since IPO date, it would be worth $0.67 as of November 11, 2025 at a share price of $0.483. Whereas If you bought $1000 worth of Moleculin Biotech, Inc. (MBRX) shares 5 years ago, it would be worth $7.51 as of November 11, 2025 at a share price of $0.483.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
GlobeNewswire Inc.
Oct 30, 2025 12:40 PM GMT
HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, t
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
GlobeNewswire Inc.
Oct 29, 2025 12:35 PM GMT
HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, t
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
GlobeNewswire Inc.
Oct 23, 2025 12:00 PM GMT
Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic cancer HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE)